X4 Pharmaceuticals Inc. (XFOR)
NASDAQ: XFORHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
XFOR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $278.60M
- P/E (TTM)
- 140.50
- EPS (TTM)
- $0.02
- Dividend yield
- None
- 52-week range
- 2.70 – 4.83
- Day range
- 2.71 – 2.86
- Volume / Avg
- 434.33K / 849.98K
- Beta
- —
- Shares outstanding
- 99.15M
- Next earnings
- Nov 4, 2026
52-week range
XFOR stock today
Shares of X4 Pharmaceuticals (XFOR) finished higher on Oct 7 at $2.81, a gain of 1.44% or $0.04 per share, versus the S&P 500's 0.22% decline. Shares are 41.8% below their 52-week high of $4.83, set on Mar 10, 2026 and 4.1% above the 52-week low of $2.70, near the bottom of the past year's range. XFOR is down 29.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 18.3%.
X4 Pharmaceuticals trades at 140.5x its trailing twelve-month earnings per share of $0.02. X4 Pharmaceuticals's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About X4 Pharmaceuticals
Company profileX4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA
- Employees
- 45
- IPO year
- 2017
- Website
- x4pharma.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$11.60+312.81%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.19
X4 Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VNDAVanda Pharmaceuticals Inc. | 4.56 | +0.89% | $275.71M | vs XFOR |
| BBOTBridgeBio Oncology Therapeutics Inc. | 3.44 | -1.71% | $275.80M | vs XFOR |
| LXEOLexeo Therapeutics Inc. | 3.31 | +0.30% | $271.71M | vs XFOR |
| RCKTRocket Pharmaceuticals Inc. | 2.54 | +2.22% | $278.28M | vs XFOR |
| EYPTEyePoint Inc. | 3.32 | +4.73% | $278.35M | vs XFOR |
| IKTInhibikase Therapeutics Inc. | 1.94 | -2.02% | $270.70M | vs XFOR |
| FULCFulcrum Therapeutics Inc. | 3.67 | -0.54% | $280.01M | vs XFOR |
| LRMRLarimar Therapeutics Inc. | 2.75 | -1.08% | $285.68M | vs XFOR |
Indexes, lists and sector
Appears in lists
X4 Pharmaceuticals stock FAQ
What is X4 Pharmaceuticals's stock price today?
XFOR last traded at $2.81 as of Oct 7, 4:00 PM EDT, up 1.44% on the day. Prices are delayed at least 15 minutes.
Does X4 Pharmaceuticals pay a dividend?
No. X4 Pharmaceuticals does not currently pay a regular cash dividend.
When is X4 Pharmaceuticals's next earnings date?
X4 Pharmaceuticals is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.19.
What is XFOR's P/E ratio?
XFOR trades at a trailing P/E ratio of 140.50.
Has XFOR ever split its stock?
Yes. The most recent XFOR stock split was a 1-for-30 split on Apr 28, 2025, one of 2 splits on record.
What is the XFOR 52-week high?
The 52-week high for XFOR is $4.83 and the 52-week low is $2.70. The stock is currently 41.8% below its high.